OX-2膜糖蛋白对冠心病合并糖尿病患者IL-6表达的影响

The Effect of OX-2 Membrane Glycoprotein on the Expression of IL-6 in Patients with Coronary Heart Disease Combined with Diabetes

摘要: 目的：探讨OX-2膜糖蛋白(CD200)对冠心病合并糖尿病患者体内慢性炎症的调控作用。方法：选取2023年3月~2024年3月在临沂市中心医院就诊的符合纳入标准的冠心病患者、糖尿病患者、冠心病合并糖尿病患者3组各20例共60例，ELISA法检测各组患者血清中CD200分子浓度，流式细胞术测定血清中白细胞介素-6 (interleukin-6, IL-6)水平，对两组数据进行统计学分析比较，进而探究CD200对慢性炎症的抑制性调控作用。结果：冠心病患者、糖尿病患者、冠心病合并糖尿病患者3组数据均高于正常参考值(0~5.3 mmol/L)，冠心病合并糖尿病组IL-6 (16.53 ± 3.88 mmol/L)水平高于冠心病组IL-6 (13.91 ± 1.70 mmol/L)，差异有统计学意义(P < 0.01)；冠心病合并糖尿病组IL-6 (16.53 ± 3.88 mmol/L)水平高于糖尿病组IL-6 (15.70 ± 5.24 mmol/L)，差异有统计学意义(P < 0.01)，糖尿病组IL-6 (15.70 ± 5.24 mmol/L)水平高于冠心病组IL-6 (13.91 ± 1.70 mmol/L)，差异有统计学意义(P < 0.01)。冠心病组CD200分子浓度(1570.98 ± 231.31 mmol/L)高于冠心病合并糖尿病组CD200 (1052.09 ± 171.82 mmol/L)水平，差异有统计学意义(P < 0.01)；糖尿病组CD200分子浓度(1063.30 ± 186.56 mmol/L)高于冠心病合并糖尿病组CD200 (1052.09 ± 171.82 mmol/L)水平，差异有统计学意义(P < 0.01)；冠心病组CD200分子浓度(1570.98 ± 231.31 mmol/L)高于糖尿病组CD200分子浓度(1063.30 ± 186.56 mmol/L)，差异有统计学意义(P < 0.01)。Spearman相关分析提示，冠心病患者血清CD200分子浓度与IL-6分子浓度呈负相关(r = −0.95, P < 0.01)；糖尿病患者血清CD200分子浓度与IL-6分子浓度呈负相关(r = −0.91, P < 0.01)；冠心病合并糖尿病患者血清CD200分子浓度与IL-6分子浓度呈负相关(r = −0.91, P < 0.01)。3组患者血清CD200分子浓度均与IL-6分子浓度呈负相关(r = −0.69, P < 0.01)。结论：CD200对IL-6起到抑制性调控作用，能够有效控制炎症，进而缓解动脉粥样硬化的病理发展进程。针对CD200的研究为临床治疗冠心病合并糖尿病患者提供新的策略。并预测开发针对CD200-CD200R轴的激动剂有望延缓冠心病合并糖尿病患者的疾病进展。

Abstract: Objective: To explore the regulatory effect of OX-2 membrane glycoprotein (CD200) on chronic inflammation in patients with coronary heart disease (CHD) complicated with diabetes mellitus (DM). Methods: A total of 60 patients were enrolled in this study, including 20 patients with CHD, 20 patients with DM, and 20 patients with CHD complicated with DM, all of whom met the inclusion criteria. The concentration of CD200 molecules in the serum of each group was determined by ELISA, and the level of IL-6 in the serum was measured by flow cytometry. The two sets of data were analyzed and compared to investigate the inhibitory regulatory effect of CD200 on chronic inflammation. Results: The data from the three groups of patients with coronary heart disease (CHD), diabetes mellitus (DM), and CHD complicated with DM were all higher than the normal reference values (0~5.3 mmol/L). The level of IL-6 in the CHD complicated with DM group (16.53 ± 3.88 mmol/L) was significantly higher than that in the CHD group (13.91 ± 1.70 mmol/L), with a statistically significant difference (P < 0.01). The level of IL-6 in the CHD complicated with DM group (16.53 ± 3.88 mmol/L) was also significantly higher than that in the DM group (15.70 ± 5.24 mmol/L), with a statistically significant difference (P < 0.01). Moreover, the level of IL-6 in the DM group (15.70 ± 5.24 mmol/L) was significantly higher than that in the CHD group (13.91 ± 1.70 mmol/L), also with a statistically significant difference (P < 0.01). The concentration of CD200 molecules in the CHD group (1570.98 ± 231.31 mmol/L) was significantly higher than that in the CHD complicated with DM group (1052.09 ± 171.82 mmol/L), with a statistically significant difference (P < 0.01). The molecular concentration of CD200 in the diabetic group (1063.30 ± 186.56 mmol/L) was higher than that in coronary heart disease complicated with diabetes (1052.09 ± 171.82 mmol/L), there was a significant difference (P < 0.01). The concentration of CD200 molecules in the CHD group (1570.98 ± 231.31 mmol/L) was significantly higher than that in the DM group (1063.30 ± 186.56 mmol/L), with a statistically significant difference (P < 0.01). Spearman correlation analysis revealed a negative correlation between the serum CD200 molecule concentration and IL-6 molecule concentration in patients with CHD (r = −0.95, P < 0.01); Similarly, a negative correlation was observed between serum CD200 molecule concentration and IL-6 molecule concentration in patients with DM (r = −0.91, P < 0.01), as well as in patients with CHD complicated with DM (r = −0.91, P < 0.01). The serum CD200 molecule concentrations in all three patient groups showed a negative correlation with IL-6 molecule concentrations (r = −0.69, P < 0.01). Conclusion: CD200 exerts inhibitory regulatory effects on IL-6, effectively controlling inflammation and alleviating the pathological progression of atherosclerosis. Research on CD200 provides new strategies for the clinical treatment of patients with coronary heart disease combined with diabetes. It is also predicted that the development of agonists targeting the CD200-CD200R axis is expected to delay disease progression in patients with coronary heart disease combined with diabetes.